Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
320.5 USD | -0.14% | +4.79% | -29.98% |
May. 02 | Cigna sees strong annual profit on lower costs, pharmacy benefit strength | RE |
Apr. 26 | Deutsche Bank Adjusts Price Target on Humana to $341 From $355 | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The stock, which is currently worth 2024 to 0.39 times its sales, is clearly overvalued in comparison with peers.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.98% | 38.63B | A- | ||
+11.75% | 122B | A- | ||
+14.04% | 96.87B | B- | ||
+0.81% | 39.92B | B- | ||
-5.99% | 19.91B | B- | ||
-14.69% | 3.05B | C+ | ||
-23.00% | 1.26B | B- | ||
-27.00% | 345M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HUM Stock
- Ratings Humana Inc.